Author:
Liu Chao,Ruan Yuli,Huang Rui,Fang Lin,Wu Tong,Lv Ying,Cui Luying,Liao Yuanyu,Wang Bojun,Chen Zhuo,Su Dan,Ma Yue,Han Shuling,Guan Xin,Cui Jie,Yao Yang,Wang Yao,Wang Mengmeng,Liu Ruiqi,Zhang Yanqiao
Abstract
Abstract
Background
Although, immune checkpoint inhibitors (ICIs) have been widely applied in the therapy of malignant tumors, the efficacy and safety of ICIs in patients with tumors and pre-existing CAD, especially chronic coronary syndromes (CCS) or their risk factors (CRF), is not well identified.
Methods
This was a nationwide multicenter observational study that enrolled participants who diagnosed with solid tumors and received ICIs therapy. The main efficacy indicators were progression-free survival (PFS) and overall survival (OS), followed by objective response rate (ORR) and disease control rate (DCR). Safety was assessed by describing treatment-related adverse events (TRAEs) during ICIs therapy evaluated by the Common Terminology Criteria for Adverse Events 5.0 (CTCAE 5.0).
Results
In the current research, we retrospectively analyzed the data of 551 patients diagnosed with solid tumors and received ICIs therapy, and these patients were divided into CCS/CRF group and non-CCS/CRF group. Patients with CCS/CRF had more favorable PFS and OS than patients without CCS/CRF (P < 0.001) and the pre-existing CCS/CRF was a protective factor for survival. The ORR (51.8% vs. 39.1%) and DCR (95.8% vs. 89.2%) were higher in CCS/CRF group than in non-CCS/CRF group (P = 0.003, P = 0.006). In this study, there was no significant difference in treatment-related adverse events (TRAEs), including immune-related adverse events (irAEs), between the two groups.
Conclusions
We concluded that ICIs appear to have better efficacy in malignant solid tumor patients with pre-existing CCS/CRF and are not accompanied by more serious irAEs.
Funder
National Natural Science Foundation of China
the Natural Science Funding of Heilongjiang
Key R&D Project of Heilongjiang Province
Publisher
Springer Science and Business Media LLC